Show filters
Radiopharmacy: past, present and future
Radiopharmaceuticals allow some types of cancer to be targeted with tailor-made therapies. The current state of the art was preceded by decades of intensive research – and the future promises even better treatment options.
Taking the fear out of cancer
Researchers at PSI are developing new technologies and drugs to eliminate tumours more effectively: with greater precision and personalised approaches
Using terbium against lymphoma
Promising laboratory experiments at PSI show that radionuclide therapy with the radioactive element terbium could combat lymphoma effectively.
New approaches to cancer treatment
The ETH/PHRT-funded clinical studies “RAPID 01” and “PROGNOSTICS” have successfully started recruiting patients.
IMPACT: Upgrade at PSI research facility approved
Financing for renovations to PSI’s proton accelerator facility has been approved by the Swiss Parliament.
IMPACT for Swiss society
World leader in muons and in production of medical radionuclides: The far-reaching significance of the planned upgrade.
Protons and other particles: The HIPA facility turns 50
Since 1974 HIPA has been accelerating protons for research.
„IMPACT is very important in terms of international competition“
Daniela Kiselev talks about the upgrade planned at PSI's proton accelerator facility.
Terbium-161: new radionuclide therapy hits the clinic
Highly targeted cancer treatment has the potential to eliminate ultra-small cancer lesions that cause disease recurrence.
Fighting tumours down to the last cancer cell
A project that promises to improve the chances of survival for prostate cancer patients has received 2 million Swiss francs in funding.
Radionuclides for personalised medicine
TATTOOS is part of the upgrade project IMPACT. Roger Schibli explains its importance for the future of cancer treatment.
A two-part upgrade for the proton accelerator
A two-part upgrade is planned for HIPA starting in 2025. Preparations are already under way.